Generic drug: selpercatinib

Brand name: Retevmo

What is Retevmo (selpercatinib), and how does it work?

Retevmo (selpercatinib) is a prescription medicine that is used to treat certain cancers caused by abnormal RET genes in:

  • adults with non-small cell lung cancer (NSCLC) that has spread.
  • adults and children 12 years of age and older with advanced medullary thyroid cancer (MTC) or MTC that has spread who require a medicine by mouth or injection (systemic therapy).
  • adults and children 12 years of age and older with advanced thyroid cancer or thyroid cancer that has spread who require a medicine by mouth or injection (systemic therapy) and who have received radioactive iodine and it did not work or is no longer working.

Your healthcare provider will perform a test to make sure that Retevmo is right for you. It is not known if Retevmo is safe and effective in children younger than 12 years of age.

What are the side effects of Retevmo?

The most common side effects of Retevmo include:

Retevmo may affect fertility in females and males, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you.

These are not all the possible side effects with Retevmo.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is the dosage for Retevmo?

Patient Selection

Select patients for treatment with Retevmo based on the presence of a RET gene fusion (NSCLC or thyroid cancer) or specific RET gene mutation (MTC) in tumor specimens or plasma. An FDA-approved test for the detection of RET gene fusions and RET gene mutations is not currently available.

Important Administration Instructions

Retevmo may be taken with or without food unless coadministrated with a proton pump inhibitor (PPI).

Recommended Dosage

The recommended dosage of Retevmo based on body weight is:

  • Less than 50 kg: 120 mg
  • 50 kg or greater: 160 mg

Take Retevmo orally twice daily (approximately every 12 hours) until disease progression or unacceptable toxicity.

Swallow the capsules whole. Do not crush or chew the capsules.

Do not take a missed dose unless it is more than 6 hours until next scheduled dose.

If vomiting occurs after Retevmo administration, do not take an additional dose and continue to the next scheduled time for the next dose.

Dosage Modifications For Concomitant Use Of Acid-Reducing Agents

Avoid concomitant use of a PPI, a histamine-2 (H2) receptor antagonist, or a locally-acting antacid with Retevmo. If concomitant use cannot be avoided:

  • Take Retevmo with food when coadministered with a PPI.
  • Take Retevmo 2 hours before or 10 hours after administration of an H2 receptor antagonist.
  • Take Retevmo 2 hours before or 2 hours after administration of a locally-acting antacid.

Dosage Modifications For Adverse Reactions

The recommended dose reductions for adverse reactions are provided in Table 1.

Table 1: Recommended Retevmo Dose Reductions for Adverse Reactions

Dose ReductionPatients Weighing Less Than 50 kgPatients Weighing 50 kg or Greater
First80 mg orally twice daily120 mg orally twice daily
Second40 mg orally twice daily80 mg orally twice daily
Third40 mg orally once daily40 mg orally twice daily

Permanently discontinue Retevmo in patients unable to tolerate three dose reductions.

The recommended dosage modifications for adverse reactions are provided in Table 2.

Table 2: Recommended Retevmo Dosage Modifications for Adverse Reactions

Adverse ReactionSeverityDosage Modification
HepatotoxicityGrade 3 or Grade 4
  • Withhold Retevmo and monitor AST/ALT once weekly until resolution to Grade 1 or baseline.
  • Resume at reduced dose by 2 dose levels and monitor AST and ALT once weekly until 4 weeks after reaching dose taken prior to the onset of Grade 3 or 4 increased AST or ALT.
  • Increase dose by 1 dose level after a minimum of 2 weeks without recurrence and then increase to dose taken prior to the onset of Grade 3 or 4 increased AST or ALT after a minimum of 4 weeks without recurrence.
HypertensionGrade 3
  • Withhold Retevmo for Grade 3 hypertension that persists despite optimal antihypertensive therapy. Resume at a reduced dose when hypertension is controlled.
 Grade 4
  • Discontinue Retevmo.
QT Interval Prolongation Grade 3
  • Withhold Retevmo until recovery to baseline or Grade 0 or 1.
  • Resume at a reduced dose.
Grade 4
  • Discontinue Retevmo
Hemorrhagic Events Grade 3 or Grade 4
  • Withhold Retevmo until recovery to baseline or Grade 0 or 1.
  • Discontinue Retevmo for severe or life-threatening hemorrhagic events.
Hypersensitivity ReactionsAll Grades
  • Withhold Retevmo until resolution of the event. Initiate corticosteroids.
  • Resume at a reduced dose by 3 dose levels while continuing corticosteroids.
  • Increase dose by 1 dose level each week until the dose taken prior to the onset of hypersensitivity is reached, then taper corticosteroids.

Dosage Modifications For Concomitant Use Of Strong And Moderate CYP3A Inhibitors

Avoid concomitant use of strong and moderate CYP3A inhibitors with Retevmo. If concomitant use of a strong or moderate CYP3A inhibitor cannot be avoided, reduce the Retevmo dose as recommended in Table 3. After the inhibitor has been discontinued for 3 to 5 elimination half-lives, resume Retevmo at the dose taken prior to initiating the CYP3A inhibitor.

Table 2: Recommended Retevmo Dosage for Concomitant Use of Strong and Moderate CYP3A Inhibitors

Current Retevmo DosageRecommended Retevmo Dosage
Moderate CYP3A InhibitorStrong CYP3A Inhibitor
120 mg orally twice daily80 mg orally twice daily40 mg orally twice daily
160 mg orally twice daily120 mg orally twice daily80 mg orally twice daily

Dosage Modification For Severe Hepatic Impairment

Reduce the recommended dosage of Retevmo for patients with severe hepatic impairment as recommended in Table 4 [see Use In Specific Populations].

Table 3: Recommended Retevmo Dosage for Severe Hepatic Impairment

Current Retevmo DosageRecommended Retevmo Dosage
120 mg orally twice daily80 mg orally twice daily
160 mg orally twice daily80 mg orally twice daily

QUESTION

Lung cancer is a disease in which lung cells grow abnormally in an uncontrolled way. See Answer

What drugs interact with Retevmo?

Effects Of Other Drugs On Retevmo

Acid-Reducing Agents
  • Concomitant use of Retevmo with acid-reducing agents decreases selpercatinib plasma concentrations, which may reduce Retevmo anti-tumor activity.  
  • Avoid concomitant use of PPIs, H2 receptor antagonists, and locally-acting antacids with Retevmo. If coadministration cannot be avoided, take Retevmo with food (with a PPI) or modify its administration time (with a H2 receptor antagonist or a locally-acting antacid).
Strong And Moderate CYP3A Inhibitors
  • Concomitant use of Retevmo with a strong or moderate CYP3A inhibitor increases selpercatinib plasma concentrations, which may increase the risk of Retevmo adverse reactions, including QTc interval prolongation.
  • Avoid concomitant use of strong and moderate CYP3A inhibitors with Retevmo. If concomitant use of strong and moderate CYP3A inhibitors cannot be avoided, reduce the Retevmo dosage and monitor the QT interval with ECGs more frequently.
Strong And Moderate CYP3A Inducers
  • Concomitant use of Retevmo with a strong or moderate CYP3A inducer decreases selpercatinib plasma concentrations, which may reduce Retevmo anti-tumor activity.
  • Avoid coadministration of strong or moderate CYP3A inducers with Retevmo.

Effects Of Retevmo On Other Drugs

CYP2C8 And CYP3A Substrates
  • Retevmo is a moderate CYP2C8 inhibitor and a weak CYP3A inhibitor.
  • Concomitant use of Retevmo with CYP2C8 and CYP3A substrates increases their plasma concentrations, which may increase the risk of adverse reactions related to these substrates.
  • Avoid coadministration of Retevmo with CYP2C8 and CYP3A substrates where minimal concentration changes may lead to increased adverse reactions.
  • If coadministration cannot be avoided, follow recommendations for CYP2C8 and CYP3A substrates provided in their approved product labeling.

Drugs That Prolong QT Interval

  • Retevmo is associated with QTc interval prolongation.
  • Monitor the QT interval with ECGs more frequently in patients who require treatment with concomitant medications known to prolong the QT interval.

Is Retevmo safe to use while pregnant or breastfeeding?

  • Based on findings from animal studies, and its mechanism of action, Retevmo can cause fetal harm when administered to a pregnant woman.
  • There are no available data on Retevmo use in pregnant women to inform drug-associated risk.
  • There are no data on the presence of selpercatinib or its metabolites in human milk or on their effects on the breastfed child or on milk production.
  • Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with Retevmo and for 1 week after the final dose.

SLIDESHOW

Lung Cancer: Early Signs, Symptoms, Stages See Slideshow

Summary

Retevmo (selpercatinib) is a prescription medicine that is used to treat certain cancers caused by abnormal RET genes in adults with non-small cell lung cancer (NSCLC), and adults and children 12 years of age and older with advanced medullary thyroid cancer (MTC), advanced thyroid cancer, or thyroid cancer. The most common side effects of Retevmo include increased levels of liver enzymes, increased blood sugar levels, decrease in white blood cell count, decreased protein levels (albumin) in the blood, decreased levels of calcium in the blood, dry mouth, diarrhea, increased creatinine (kidney function test), high blood pressure, and others.

Treatment & Diagnosis

Medications & Supplements

Subscribe to MedicineNet's Cancer Report Newsletter

By clicking "Submit," I agree to the MedicineNet Terms and Conditions and Privacy Policy. I also agree to receive emails from MedicineNet and I understand that I may opt out of MedicineNet subscriptions at any time.

Health Solutions From Our Sponsors

FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Medically Reviewed on 4/5/2021
References
All sections courtesy of the U.S. Food and Drug Administration